LGND Financial Facts
Income tax expense (benefit): -160KGain on sale of a product line: 0
See Full Income Statement
Short-term investments: 37.54M
Accumulated deficit: -428M
See Full Balance Sheet
Ligand Pharmaceuticals Inc. (LGND) Earnings
|
Expand Research on LGND
| Next EPS Date | 8/7/26 *Est. | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +29.1% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +4.7% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/6/26  |
Q126 | N/A | $1.82 | N/A | N/A | $59.97M | = | N/A | N/A | ||
| 2/26/26 | Q425 | $2.02 | $1.49 | +$0.53 | $59.66M | $55.59M | = |  | | Details | |
| 11/6/25 | Q325 | $3.09 | $1.93 | +$1.16 | $115.46M | $57.22M | = | | | Details | |
| 8/7/25 | Q225 | $1.60 | $1.43 | +$0.17 | $47.63M | $43.74M | = | | | Details | |
| 5/8/25 | Q125 | $1.33 | $1.22 | +$0.11 | $45.33M | $37.92M | = | | | Details | |
| 2/27/25 | Q424 | $1.27 | $1.18 | +$0.09 | $42.81M | $39.03M | = | | | Details | |
| 2/18/25 |
Q424 | N/A | $1.18 | N/A | N/A | $39.03M | = | N/A | N/A | ||
| 2/17/25 |
Q424 | N/A | $1.18 | N/A | N/A | $39.03M | = | N/A | N/A |
